ClinicalTrials.gg
RecruitingNCT05139849VAST-AUpdated Nov 12, 2026

VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial

A Phase 3 interventional study of Vasopressin; Methylprednisolone; Hydrocortisone in Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial, sponsored by Tiohundra AB. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Tiohundra AB · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 12, 2026Study documents postedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
784
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing Arginine Vasopressin in Diabetes Insipidus — 12 open to participants now, 12 under way, 2 of them phase 3. Arginine Vasopressin · Diabetes Insipidus.

Planned enrollment
3rd of 43
784 · median 105
Started
2026
with 2 others
Phase 3
5 of 43
2 open now
Primary completion
2029-01
later than 11 of 11 live
Registered
33rd of 43
by date

Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 33rd registered.

Diabetes Insipidus

191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.

Browse Diabetes Insipidus studies →

Open to participants now

12 of the 43 studies testing Arginine Vasopressin in Diabetes Insipidus are open now, in 5 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Arginine Vasopressin

Arginine Vasopressin: first FDA approval 2020 (VASOPRESSIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Diabetes Insipidus studies recruiting now, 16 (53%) set no upper age limit and 11 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing Arginine Vasopressin in Diabetes Insipidus, or all of them as a file.
02

Study summary

This is an investigator initiated randomized, placebo controlled, open label, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, after now completed pilot phase. Based on preliminary assumptions, to confirm or reject an increase in survival from 16% to 24%, about 784 patients will be randomized in the study. In hospital cardiac arrest patients meeting criteria(s) for adrenaline administration according to current ERC guidelines, men > 18 years and women > 50, are eligible for randomization in the study.

Patients with do not resuscitate (DNR) decision will be excluded. Patients will be randomized to, in addition to adrenaline, either treatment with vasopressin and steroids (intervention) or standard care (control) Primary outcome is survival at 30 days.

Read the detailed description

An initial VAST-A pilot study with a previous protocol was conducted 2022-2024 to test feasibility and safety. The pilot results and experiences led to this VAST-A main trial with a revised protocol.

03

Conditions studied

  • Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Witnessed inhospital cardiac arrest, who meet the criteria for adrenaline administration according to current ERC guidelines
  • Men > 18 years and women > 50 years.

Exclusion criteria

Exclusion Criteria:

  • Patients with a do not resuscitate (DNR) decision
  • Peroperative cardiac arrest
  • Out of hospital cardiac arrest, including rearrest at the emergency department or the intensive care unit.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
784 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Adrenaline, vasopressin and steroids arm (intervention) 1. At randomization 1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR. 1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR 2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 5 days.

    Drug: Vasopressin; Methylprednisolone; Hydrocortisone

  • No intervention
    Control

    Standard care in cardiac arrest

Interventions

  • DrugVasopressin; Methylprednisolone; Hydrocortisone

    Drug pages: Arginine VasopressinStudies of Arginine VasopressinArginine Vasopressin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · HydrocortisoneStudies of HydrocortisoneHydrocortisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow. Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury.

06

What researchers measure

Primary outcomes

  1. Survival at 30 days

    Survival at 30 days

    Time frame: Survival at 30 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Andersen LW, Holmberg MJ, Hoybye M, Isbye D, Kjaergaard J, Darling S, Zwisler ST, Larsen JM, Rasmussen BS, Iversen K, Schultz M, Sindberg B, Fink Valentin M, Granfeldt A. Vasopressin and methylprednisolone and hemodynamics after in-hospital cardiac arrest - A post hoc analysis of the VAM-IHCA trial. Resuscitation. 2023 Oct;191:109922. doi: 10.1016/j.resuscitation.2023.109922. Epub 2023 Aug 3. PubMed 37543161 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Nov 2021 → Oct 2026, primary completion Jan 2027 → Jan 2029 and completion Apr 2027 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 1, 2021
StartActual
Oct 12, 2026was Nov 2021
Primary completionEst.
Jan 31, 2029was Jan 2027
CompletionEst.
Jun 30, 2029was Apr 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 17, 2021→Oct 12, 2026
Nov 12, 2026
Primary completion
Jan 31, 2027→Jan 31, 2029
Nov 12, 2026
Study completion
Apr 30, 2027→Jun 30, 2029
Nov 12, 2026
Enrollment
1276→784
Nov 12, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 2 added, 3 removed
What changed in the criteria
Inclusion criteria
  • AddedWitnessed inhospital cardiac arrest, who meet the criteria for adrenaline administration according to current ERC guidelines
  • EditedHospitalized menMen > 18 years and hospitalized women > 50 years.
Exclusion criteria
  • RemovedPatients not capable to comprehend information to decide about participation in the study
  • RemovedWomen considered of childbearing potential (WOCBP) i. e. premenopausal women
  • EditedPatients with a do not resuscitate (DNR) descisiondecision
  • RemovedPrior enrollment and randomization in the trial
  • AddedPeroperative cardiac arrest
  • AddedOut of hospital cardiac arrest, including rearrest at the emergency department or the intensive care unit.
Nov 12, 2026
Interventions
Removed Drug: Sodium chloride
Nov 12, 2026
Documents
Nov 12, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37543161 ↗
Nov 12, 2026
Contact
Study contact changed: s•••@tiohundra.se · •••7953→s•••@tiohundra.se · •••7953; added l•••@ki.se · •••8748. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Documents Study protocol ↗ posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37543161 ↗
    Start date Nov 17, 2021→Oct 12, 2026
    Primary completion Jan 31, 2027→Jan 31, 2029
    Study completion Apr 30, 2027→Jun 30, 2029
    Enrollment 1276→784
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited, 2 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • AddedWitnessed inhospital cardiac arrest, who meet the criteria for adrenaline administration according to current ERC guidelines
    • EditedHospitalized menMen > 18 years and hospitalized women > 50 years.
    Exclusion criteria
    • RemovedPatients not capable to comprehend information to decide about participation in the study
    • RemovedWomen considered of childbearing potential (WOCBP) i. e. premenopausal women
    • EditedPatients with a do not resuscitate (DNR) descisiondecision
    • RemovedPrior enrollment and randomization in the trial
    • AddedPeroperative cardiac arrest
    • AddedOut of hospital cardiac arrest, including rearrest at the emergency department or the intensive care unit.
    Interventions Removed Drug: Sodium chloride
    Contact Study contact changed: s•••@tiohundra.se · •••7953→s•••@tiohundra.se · •••7953; added l•••@ki.se · •••8748. See the current contact
    + 5 other changes: identifiers, verification date, description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05139849
Lead sponsor
Tiohundra AB
Collaborators
Sahlgrenska University Hospital, Stockholm South General Hospital
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Oct 12, 2026
Primary completion
Jan 31, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Sune Forsberg, Associate Professor
Contact
sune.forsberg@tiohundra.se
+46722037953
Lis Frykler Abazi, MD, PhD
Contact
lis.abazi@ki.se
+46 735258748
Sune Forsberg, MD, Associate Professor
principal investigator · Tiohundra AB
Lis Frykler Abazi, MD, PhD
study chair · Norrtälje Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arginine Vasopressin · Methylprednisolone · Hydrocortisone

Start the discussion